Editas Medicine Inc reports a Return on Equity (ROE) of -2,471.73%.

What is EDIT's dividend yield?

Editas Medicine Inc offers a dividend yield of 0.00%.

What is EDIT's Quality Score?

Our AI rates EDIT's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy EDIT?

Our AI Timing Score for EDIT is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does EDIT belong to?

Editas Medicine Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Editas Medicine Inc (EDIT) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

EDIT AI Analysis Summary

Our AI summary for EDIT: Editas Medicine Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -2,471.73%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

EDIT

Editas Medicine Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 98

USD 2.77

0.12 (4.53%) Day Change

Watchlist Portfolio Compare Chart

3.22

D/E

-2,471.7%

ROE

-73.0%

ROA

0.00%

Div Yield

EDITAS MEDICINE INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 2.77 Price 0.12 (4.53%) Day Change	NEWS SCORE: 98

EDIT, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	98
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	2.77
PBV / Sector	92.26 / 44,022.72
Earning Per Share	-0.74

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	4.91 M GREAT
Average 1W Daily Value	3.11 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-281.59 / 98.24
NPM Average (%) / Sector	-528.63 / -1,697.63
NPM Change Average (%) / Sector	29.54 / 5,097.97 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-72.96 / 185,260.96
ROA Average (%) / Sector	-59.72 / 36,684.70
ROA Change Average (%) / Sector	28.01 / 422,221.66 GREAT
ROE (%) / Sector	-2,471.73 / 243,762.23
ROE Average (%) / Sector	-667.08 / 48,758.47
ROE Change Average (%) / Sector	208.34 / 424,968.10 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:07
Symbol	EDIT
Name	EDITAS MEDICINE INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	153.46 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	406.67 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 11 Hurley Street, Cambridge, MA, United States, 02141

Phone: 617 401 9000

Website: https://www.editasmedicine.com

Employees: 87

Sector: Healthcare >> Biotechnology

Description: Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.